Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-08-21
2009-06-30
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S280000, C544S262000, C514S262100
Reexamination Certificate
active
07553839
ABSTRACT:
The present invention relates to compounds of the general formula (I) which are inhibitors of purine muclioside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5′-methylthioadenosine phosphorylases (MTAP), 5′-methylthioadenosine mucliosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.
REFERENCES:
patent: 5985848 (1999-11-01), Furneaux et al.
patent: 6066722 (2000-05-01), Furneaux et al.
patent: 6228847 (2001-05-01), Furneaux et al.
patent: 6379911 (2002-04-01), Schramm et al.
patent: 6458799 (2002-10-01), Montgomery et al.
patent: 6492347 (2002-12-01), Furneaux et al.
patent: 6693193 (2004-02-01), Furneaux et al.
patent: 6764829 (2004-07-01), Schramm et al.
patent: 6803455 (2004-10-01), Furneaux et al.
patent: 7022852 (2006-04-01), Furneaux et al.
patent: 7098334 (2006-08-01), Furneaux et al.
patent: 7109331 (2006-09-01), Furneaux et al.
patent: 7211653 (2007-05-01), Furneaux et al.
patent: 7211677 (2007-05-01), Furneaux et al.
patent: 2006/0217551 (2006-09-01), Evans et al.
patent: WO 99/19338 (1999-04-01), None
patent: WO 02/18371 (2002-03-01), None
patent: WO 2005/118532 (2005-12-01), None
patent: WO 2006/014913 (2006-02-01), None
patent: WO 2006/123953 (2006-11-01), None
patent: WO 2007/069923 (2007-06-01), None
patent: WO 2007/097647 (2007-08-01), None
patent: WO 2007/097648 (2007-08-01), None
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Anonymous, BioCryst News. <http://shareholder.com/biocryst
ews/19980429-25543cfm?ReleaseID=25543>, Apr. 29, 1998.
Evans G.B. et al., “Exploring Structure-Activity Relationships of Transition State Analogues of Human Purine Nucleoside Phosphorylase.” Journal of Medicinal Chemistry, 46:3412-3423, 2003.
Lewansowicz A. et al., “Over-the-Barrier Transition State Analogues and Crystal Structure with Mycobacterium Tuberculosis Purine Nucleoside Phosphorylase.” Biochemistry, 42:6057-6066, 2003.
Brakta M et al, entitled “Efficient Synthesis of 3H,5H-Pyrrolo[3,2-d] pyrimidin-4-one,” J. Chem. Soc. Perkin Trans., 1992, vol. 1, pp. 1883-1884.
Evans G B et al. “Synthesis of a transition state analogue inhibitor of purine nucleoside phosphorylase via the Mannich reaction,” Organic Letters 2003, 5(20), 3639-3640.
Filichev V V et al., entitled “Synthesis of 1′-aza-C-nucleosides from (3R,4R)-4-(hydroxymethyl)pyrrolidin-3-ol,” Tetrahedron 57 (2001) 9163-9168.
Galeazzi, R et al., “Chiral 3-hydroxypyrrolidin-2-ones from a Baylis-Hillman adduct: convergent, stereoselective synthesis of glycosidase inhibitor,” Tetrahedron: Asymmetry, vol. 15, pp. 3249-3256, 2004.
Kamath V P et al., entitled “Synthesis of a potent transition-state inhibitor of 5′-Deoxy-5′-methylthioadenosine phosphorylase,” J. Med. Chem. 2004, 47, 1322-1324.
Kametani, T et al., “Studies on the Syntheses of Heterocylic Compounds. 762. Synthesis of 3-benzyl-6-methyl-2-oxo-3,6-diazabicyclo[3.1.0]hexane as a synthetic intermediate of mitomycins,” Tetrahedron, 1979, 35(3), pp. 313-316.
Karlsson S et al., entitled “Synthesis of enantiomerically pure 4-substituted pyrrolidin-3-ols via asymmetric 1,3-dipolar cycloaddition,” Tetrahedron: Asymmetry 12 (2001) 1977-1982.
International Searching Authority, “Written Opinion of the International Searching Authority,” for International Application No. PCT/NZ2004/000017, 3 pages, mailing date: May 7, 2004.
“International Preliminary Report on Patentability,” for International Application No. PCT/NZ2004/000017, 3 pages, date completed: Jan. 18, 2005.
“International Preliminary Examination Report,” for International Application No. PCT/NZ2003/000186, 3 pages, date completed: May 5, 2004.
Lewandowicz A et al., entitled “Energetic Mapping of Transition State Analogue Internations with Human and Plasmodium falciparum Purine Nucleotide Phosphorylases” Journal of Biological Chemistry, 2005, 280(34), 30320-30328.
Lim M-I et al., entitled “A New Synthesis of Pyrrolo[3,2-d]pyrimidines (“9-Deazapurines”) via 3-Amino-2-carboalkoxypyrroles,” J. Org. Chem., 1979, vol. 44, No. 22, pp. 3826-3829.
Miles R W et al., entitled “One-Third-the-Sites Transition-State Inhibitors for Purine Nucleoside Phosphorylase,” Biochemistry, 1998, vol. 37, No. 24, pp. 6-12.
STN File CA abstract No. 91-123648 (4 pages), Jan. 4, 2006.
Taylor E C et al., entitled “An Expeditious Synthesis of 2-Amino-4(3H)-oxo-5H-pyrrolo[3,2-d] pyrimidine (9-Deazaguanine),” Tetrahedron Letters, 1993, vol. 34, No. 29, pp. 4595-4598.
Evans Gary Brian
Furneaux Richard Hubert
Lenz Dirk Henning
Schramm Vern L.
Tyler Peter Charles
Albert Einstein College of Medicine of Yeshiva University
Amster Rothstein & Ebenstein LLP
Industrial Research Limited
Moore Susanna
Wilson James O
LandOfFree
5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4055054